Intas enters into exclusive licence agreement with Syna to commercialise LB-0702 in gobal markets

Syna Therapeutics has signed a global rights licensing deal with Intas Pharma to commercialise its biosimilar drug LB0702. Under the terms of the agreement, Intas has been granted exclusive licensing rights to commercialise LB-0702 worldwide. Syna will develop and manufacture LB-0702 and supply the product to Intas and its worldwide affiliates. As one of the key players in the global biosimilar market, Accord Healthcare, Intas’s wholly-owned subsidiary, has proven commercial capabilities with one of the largest sales and distribution networks in 85 countries globally, the companies said in a joint statement.

The statement said that Syna will begin clinical trials for LB-0702 in 2023 with support from its partners Leanbio
and Reig Jofre. The company will utilise the technology platforms of Leanbio coupled with the technology production expertise of Reig Jofre at its new manufacturing plant in Barcelona, which is purposed for sterile injectables and lyophilised biopharma products.